Insight or Confusion: Survival After Response-Guided Neoadjuvant Chemotherapy in Breast Cancer
Mené sur 2 702 patientes atteintes d'un cancer de stade précoce traité par deux cycles de docétaxel, doxorubicine et cyclophosphamide (TAC), cet essai évalue, du point de vue de la survie sans maladie et de la survie globale, l'intérêt de compléter le traitement néoadjuvant par six cycles du protocole TAC pour les patientes répondant au traitement initial ou, pour les patientes ne répondant pas, par quatre cycles du protocole TAC ou une combinaison vinorelbine et capécitabine
In current clinical practice, the use of neoadjuvant chemotherapy for the treatment of breast cancer is well established. Once reserved for the treatment of locally advanced inoperable tumors, the neoadjuvant treatment strategy has been increasingly employed in operable breast cancer with good reason. This strategy offers a number of advantages over adjuvant therapy, with in vivo assessment of tumor response ranking among the most important. The neoadjuvant strategy has showngreat potential as a platform for drug development, and this has led the US Food and Drug Administration to recently strongly consider pathologic response to neoadjuvant therapy as an end point to support accelerated drug approval in high-risk early-stage breast cancer...
Journal of Clinical Oncology , éditorial en libre accès, 2013